The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients

Diabetes Care

Volumn 25, Issue 12, 2002, Pages 2153-2158

  Meyer, Laurent ^a   Bohme, Philip ^a   Delbachian, Irene ^a   Lehert, Philippe ^b,c   Cugnardey, Nathalie ^d   Drouin, Pierre ^a   Guerci, Bruno ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MONS   (Belgium)

^d LIPHA Santé   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN; RECOMBINANT HUMAN INSULIN; ANTIDIABETIC AGENT; C PEPTIDE; GLYCOSYLATED HEMOGLOBIN; PLACEBO;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; GLUCOSE BLOOD LEVEL; INSULIN INFUSION; METABOLISM; RANDOMIZED CONTROLLED TRIAL; TIME;

ADULT; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN INFUSION SYSTEMS; MALE; METFORMIN; PLACEBOS; TIME FACTORS;

EID: 0038782791     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.25.12.2153     Document Type: Article

References (33)

1. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
2. Bode BW, Steed RD, Davidson PC: Reduction in severe hypoglycemia with long-term subcutaneous insulin infusion in type 1 diabetes. Diabetes Care 19:324-327, 1996
3. Bell DSH, Ackerson C, Cutter G, Clements RS: Factors associated with discontinuation of continuous subcutaneous insulin infusion. Am J Med Sci 295:23-28, 1988
4. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T: Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 46:440-443, 1997
5. 1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps. Diabetes Care 21:977-982, 1998
6. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-872, 1998
7. Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, D'Onofrio F: Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 44:107-112, 1993
8. Robinson A, Burke J, Robinson S, Johnston D, Elkeles R: The effects of metformin on glycaemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 21:701-705, 1998
9. Yu JG, Kruszynska YT, Mulford MI, Olefsky JM: A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes 48:2414-2421, 1999
10. Pagano G, Tagliaferro V, Carta Q, Caselle M, Bozzo C, Vitelli F, Trovati M, Cocuzza E: Metformin reduces insulin requirement in type 1 (insulin-dependent) diabetes. Diabetologia 24:351-354, 1983
11. Gin H, Slama G, Weissbrodt P, Poynard T, Vexiau P, Klein J, Tchobrousky G: Metformin reduces post-prandial insulin needs in type 1 (insulin-dependent) diabetic patients: assessment by the artificial pancreas. Diabetologia 23:34-36, 1982
12. Janssen M, Rillaerts E, De Leeuw I: Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM). Biomed Pharmacother 45:363-367, 1991
13. Skyler JS, Skyler DL, Seigler DE, O'Sullivan MJ: Algorithms for adjustment of insulin dosage by patients who monitor blood glucose. Diabetes Care 4:311-318, 1981
14. Guerci B, Meyer L, Delbachian I, Kolopp M, Ziegler O, Drouin P: Blood glucose control on Sunday in IDDM patients: intensified conventional insulin therapy versus continuous subcutaneous insulin infusion. Diabetes Res Clin Pract 40:175-180, 1998
15. Davidson PC: Bolus and supplemental insulin. In Insulin Pump Therapy Book: Insights From the Experts. Fredrickson L, Ed. Sylmar, CA, MiniMed Technologies, 1995, p. 59-71
16. The Diabetes Control and Complications Trial Research Group: Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46:271-286, 1997
17. Friedewald WT, Levy RI, Frederickson J: Estimation of the concentration of low-density cholesterol in plasma without the use of the preparative ultra-centrifuge. Clin Chem 18:499-502, 1972
18. Golay A, Guillet-Dauphine N, Fendel A, Juge C, Assal J: The insulin-sparing effect of metformin in insulin-treated diabetic patients. Diabete Metab Rev 11 (Suppl. 1):S63-S67, 1995
19. Bending JJ, Collins AC, Keen H: Metformin increases response to insulin in insulin-dependent diabetes (Abstract). Diabet Med 46:555A, 1987
20. Coscelli C, Palmari V, Saccardi F, Orsola A, Bonnora E: Effect of Metformin addition to insulin in type 1 diabetes mellitus. Front Diabetes 4:253-257, 1984
21. Gin H, Messerchmitt C: Metformin improved insulin resistance in type 1, insulin-dependent, diabetic patients. Metabolism 34:923-925, 1985
22. Estrada DE, Elliott E, Zinman B, Poon I, Liu Z, Klip A, Daneman D: Regulation of glucose transport and expression of GLUT3 transporters in human circulating mononuclear cells: studies in cells from insulin-dependent diabetic and nondiabetic individuals. Metabolism 43:591-598, 1994
23. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 49:2063-2069, 2000
24. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554, 1995
25. Radziuk J, Zhang Z, Wiemsperger N, Pye S: Effects of metformin on lactate uptake and gluconeogenesis in the perfused rat liver. Diabetes 46:1406-1413, 1997
26. Mithieux G, Guignot L, Bordet JC, Wiernsperger N: Intrahepatic mechanisms underlying the effect of metformin in decreasing basal glucose production in rats fed a high-fat diet. Diabetes 51:139-143, 2002
27. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001
28. Del Prato S, Matsuda M, Simonson DC, Groop LC, Sheehan P, Leonetti F, Bonadonna RC, De Fronzo RA: Studies on the mass action effect of glucose in NIDDM and IDDM: evidence for glucose resistance. Diabetologia 40:687-697, 1997
29. Hollander P, Pi-Sunyer X, Coniff RF: Acarbose in the treatment of type 1 diabetes. Diabetes Care 20:248-253, 1997
30. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44:968-983, 1995
31. Bonora E, Muggeo M: Postprandial blood glucose as a risk factor for cardiovascular disease in type 2 diabetes: the epidemiological evidence. Diabetologia 44:2107-2114, 2001
32. Ceriello A: The emerging role of postprandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabet Med 15:188-193, 1998
33. Diabetes Control and Complications Trial Research Group: Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 18:361-376, 1995